Anti-VEGF Agents – The Importance of Early Switching when Treatment Fails
In patients with diabetic macular oedema, aflibercept is the only globally approved anti-VEGF agent that binds all ligands of VEGF receptor 1.
You will learn:
• Factors affecting the choice of anti-vascular endothelial growth factor (VEGF) agent for treating diabetic macular oedema (DME)
• Clinical trial and real-world evidence for maximising vision gains while reducing the treatment burden for patients with DME
• The principles of anti-VEGF treatment regimens for neovascular age-related macular degeneration (nAMD)
• The relevance of the molecular properties of anti-VEGF agents with regard to switching therapy.
WEBINAR HELD ON 3 NOVEMBER 2021
ATTENTIONKindly note that if you attended the live webinar, you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record the 1 CPD point from the live webinar, invalidating any additional CPD points from the report.
Please note deNovo Medica ensures uploading of your CPD points to the HPCSA: please don’t upload these yourself.
To access this module, please register or login: